News AstraZeneca and Lilly’s Alzheimer’s drug fails trial The battle to develop a drug to treat Alzheimer’s disease has been dealt a blow following disappointing phase 3 trial results.
News Lilly and Alder showcase latest migraine drug data Lilly and Alder take on the might of Novartis and Amgen
News Novartis/Amgen migraine jab works in tough-to-treat patients Novartis continues to build the case for its Aimovig migraine injection,with data showing it works in a tough-to-treat patient group.
News Lilly researches cell therapies for type 1 diabetes with Sig... Eli Lilly and Sigilon Therapeutics have announced a collaboration to develop therapies based around capsules of genetically-engineered stem cells to treat type 1 diabetes.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.